Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)

China flag China · Delayed Price · Currency is CNY
48.64
-1.01 (-2.03%)
At close: Mar 20, 2026
Market Cap23.07B +23.8%
Revenue (ttm)801.14M +122.6%
Net Income-763.31M
EPS-1.71
Shares Out464.63M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,690,882
Average Volume2,351,834
Open49.56
Previous Close49.65
Day's Range48.48 - 50.65
52-Week Range42.40 - 86.18
Beta0.04
RSI42.54
Earnings DateMar 31, 2026

About SHA:688192

Dizal (Jiangsu) Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of cancer and immunological diseases. Its assets include the ZEGFROVY, for the treatment of solid tumors; Golidocitinib to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. The company was founded in 2017 and is based in Shan... [Read more]

Sector Healthcare
Founded 2017
Employees 985
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688192
Full Company Profile

Financial Performance

In 2025, SHA:688192's revenue was 801.14 million, an increase of 122.60% compared to the previous year's 359.90 million. Losses were -763.31 million, -9.77% less than in 2024.

Financial Statements